163 related articles for article (PubMed ID: 22431915)
1. Distinct effects of contraction-induced injury in vivo on four different murine models of dysferlinopathy.
Roche JA; Ru LW; Bloch RJ
J Biomed Biotechnol; 2012; 2012():134031. PubMed ID: 22431915
[TBL] [Abstract][Full Text] [Related]
2. Myofiber damage precedes macrophage infiltration after in vivo injury in dysferlin-deficient A/J mouse skeletal muscle.
Roche JA; Tulapurkar ME; Mueller AL; van Rooijen N; Hasday JD; Lovering RM; Bloch RJ
Am J Pathol; 2015 Jun; 185(6):1686-98. PubMed ID: 25920768
[TBL] [Abstract][Full Text] [Related]
3. Extensive mononuclear infiltration and myogenesis characterize recovery of dysferlin-null skeletal muscle from contraction-induced injuries.
Roche JA; Lovering RM; Roche R; Ru LW; Reed PW; Bloch RJ
Am J Physiol Cell Physiol; 2010 Feb; 298(2):C298-312. PubMed ID: 19923419
[TBL] [Abstract][Full Text] [Related]
4. Diltiazem improves contractile properties of skeletal muscle in dysferlin-deficient BLAJ mice, but does not reduce contraction-induced muscle damage.
Begam M; Collier AF; Mueller AL; Roche R; Galen SS; Roche JA
Physiol Rep; 2018 Jun; 6(11):e13727. PubMed ID: 29890050
[TBL] [Abstract][Full Text] [Related]
5. Genetic manipulation of dysferlin expression in skeletal muscle: novel insights into muscular dystrophy.
Millay DP; Maillet M; Roche JA; Sargent MA; McNally EM; Bloch RJ; Molkentin JD
Am J Pathol; 2009 Nov; 175(5):1817-23. PubMed ID: 19834057
[TBL] [Abstract][Full Text] [Related]
6. The distribution and characterization of skeletal muscle lesions in dysferlin-deficient SJL and A/J mice.
Kobayashi K; Izawa T; Kuwamura M; Yamate J
Exp Toxicol Pathol; 2010 Sep; 62(5):509-17. PubMed ID: 19615872
[TBL] [Abstract][Full Text] [Related]
7. Dysferlinopathy Promotes an Intramuscle Expansion of Macrophages with a Cyto-Destructive Phenotype.
Baek JH; Many GM; Evesson FJ; Kelley VR
Am J Pathol; 2017 Jun; 187(6):1245-1257. PubMed ID: 28412297
[TBL] [Abstract][Full Text] [Related]
8. Characterization of dysferlin deficient SJL/J mice to assess preclinical drug efficacy: fasudil exacerbates muscle disease phenotype.
Rayavarapu S; Van der Meulen JH; Gordish-Dressman H; Hoffman EP; Nagaraju K; Knoblach SM
PLoS One; 2010 Sep; 5(9):e12981. PubMed ID: 20886045
[TBL] [Abstract][Full Text] [Related]
9. Dual effects of exercise in dysferlinopathy.
Biondi O; Villemeur M; Marchand A; Chretien F; Bourg N; Gherardi RK; Richard I; Authier FJ
Am J Pathol; 2013 Jun; 182(6):2298-309. PubMed ID: 23624156
[TBL] [Abstract][Full Text] [Related]
10. Structural and ultrastructural changes in the skeletal muscles of dysferlin-deficient mice during postnatal ontogenesis.
Chernova ON; Chekmareva IA; Mavlikeev MO; Yakovlev IA; Kiyasov AP; Deev RV
Ultrastruct Pathol; 2022 Jul; 46(4):359-367. PubMed ID: 35880824
[TBL] [Abstract][Full Text] [Related]
11. Dysferlin and animal models for dysferlinopathy.
Kobayashi K; Izawa T; Kuwamura M; Yamate J
J Toxicol Pathol; 2012 Jun; 25(2):135-47. PubMed ID: 22907980
[TBL] [Abstract][Full Text] [Related]
12. Dysferlin stabilizes stress-induced Ca2+ signaling in the transverse tubule membrane.
Kerr JP; Ziman AP; Mueller AL; Muriel JM; Kleinhans-Welte E; Gumerson JD; Vogel SS; Ward CW; Roche JA; Bloch RJ
Proc Natl Acad Sci U S A; 2013 Dec; 110(51):20831-6. PubMed ID: 24302765
[TBL] [Abstract][Full Text] [Related]
13. Diaphragm displays early and progressive functional deficits in dysferlin-deficient mice.
Barton ER; Wang BJ; Brisson BK; Sweeney HL
Muscle Nerve; 2010 Jul; 42(1):22-9. PubMed ID: 20544921
[TBL] [Abstract][Full Text] [Related]
14. Serum exosomes can restore cellular function
Dong X; Gao X; Dai Y; Ran N; Yin H
Theranostics; 2018; 8(5):1243-1255. PubMed ID: 29507617
[No Abstract] [Full Text] [Related]
15. Hip region muscular dystrophy and emergence of motor deficits in dysferlin-deficient Bla/J mice.
Nagy N; Nonneman RJ; Llanga T; Dial CF; Riddick NV; Hampton T; Moy SS; Lehtimäki KK; Ahtoniemi T; Puoliväli J; Windish H; Albrecht D; Richard I; Hirsch ML
Physiol Rep; 2017 Mar; 5(6):. PubMed ID: 28320887
[TBL] [Abstract][Full Text] [Related]
16. Effect of Ibuprofen on Skeletal Muscle of Dysferlin-Null Mice.
Collier AF; Gumerson J; Lehtimäki K; Puoliväli J; Jones JW; Kane MA; Manne S; O'Neill A; Windish HP; Ahtoniemi T; Williams BA; Albrecht DE; Bloch RJ
J Pharmacol Exp Ther; 2018 Mar; 364(3):409-419. PubMed ID: 29284661
[TBL] [Abstract][Full Text] [Related]
17. A promotive effect for halofuginone on membrane repair and synaptotagmin-7 levels in muscle cells of dysferlin-null mice.
Barzilai-Tutsch H; Dewulf M; Lamaze C; Butler Browne G; Pines M; Halevy O
Hum Mol Genet; 2018 Aug; 27(16):2817-2829. PubMed ID: 29771357
[TBL] [Abstract][Full Text] [Related]
18. Impaired recovery of dysferlin-null skeletal muscle after contraction-induced injury in vivo.
Roche JA; Lovering RM; Bloch RJ
Neuroreport; 2008 Oct; 19(16):1579-84. PubMed ID: 18815587
[TBL] [Abstract][Full Text] [Related]
19. Anti-TNF therapy using etanercept suppresses degenerative and inflammatory changes in skeletal muscle of older SJL/J mice.
Nemoto H; Konno S; Sugimoto H; Nakazora H; Nomoto N; Murata M; Kitazono H; Fujioka T
Exp Mol Pathol; 2011 Jun; 90(3):264-70. PubMed ID: 21324312
[TBL] [Abstract][Full Text] [Related]
20. Bone marrow transplantation in dysferlin-deficient mice results in a mild functional improvement.
Flix B; Suárez-Calvet X; Díaz-Manera J; Santos-Nogueira E; Mancuso R; Barquinero J; Navas M; Navarro X; Illa I; Gallardo E
Stem Cells Dev; 2013 Nov; 22(21):2885-94. PubMed ID: 23777246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
